The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease

The Danish giant’s GLP-1 agonist blockbuster is effective against diabetes, obesity and cardiovascular disease. Now kidney disease can be added to the list after a Phase III trial was halted for efficacy.